DiscoveryProbe™ FDA-approved Drug Library: High-Impact Screening for Drug Repositioning and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by the FDA, EMA, HMA, CFDA, or PMDA, or listed in global pharmacopeias (ApexBio L1021). Each compound’s mechanism of action is well-annotated, spanning receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signaling regulators. The library is pre-dissolved in DMSO at 10 mM and formatted for high-throughput (HTS) and high-content screening (HCS) workflows. Recent studies, such as the use of 5-aminosalicylic acid in osteoarthritis models, illustrate the platform’s utility in identifying new therapeutic targets and repositioning opportunities (Kim et al., 2024). The library accelerates translational research by enabling rapid, systematic evaluation of clinically validated molecules.

Biological Rationale

Drug discovery increasingly relies on libraries of characterized molecules for efficient screening and repositioning. The DiscoveryProbe™ FDA-approved Drug Library offers a collection of 2,320 compounds with established safety and efficacy profiles (ApexBio L1021). These compounds represent diverse therapeutic classes, including anticancer agents (e.g., doxorubicin), antidiabetics (e.g., metformin), and cardiovascular drugs (e.g., atorvastatin). Such diversity enables researchers to interrogate a wide range of biological targets and pathways. The value of FDA-approved libraries is underscored by recent successes in drug repositioning, where known drugs demonstrate efficacy in new indications, as with 5-aminosalicylic acid modulating the OSCAR-PPARγ axis in osteoarthritis (Kim et al., 2024). This strategy reduces development time by leveraging pre-existing pharmacokinetic, safety, and regulatory data (DiscoveryProbe: High-Impact Screening), extending the impact of each compound beyond its original indication.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library’s compounds are annotated by mechanism, including:

• Receptor agonists and antagonists (e.g., beta-blockers, opioid antagonists).
• Enzyme inhibitors (e.g., kinase, protease, and HDAC inhibitors).
• Ion channel modulators (e.g., calcium channel blockers).
• Signaling pathway regulators (e.g., PI3K/AKT, MAPK pathway modulators).

Compounds are supplied as 10 mM solutions in DMSO, supporting direct use in HTS/HCS platforms. Each is traceable to regulatory documentation, ensuring data integrity and reproducibility (Atomic Evidence). For example, 5-aminosalicylic acid, originally approved for inflammatory bowel disease, was recently validated to inhibit the OSCAR-collagen II interaction, modulating chondrocyte PPARγ activity and suppressing OA progression (Kim et al., 2024).

Evidence & Benchmarks

• The library contains 2,320 compounds, each with regulatory approval by FDA, EMA, HMA, CFDA, or PMDA, or inclusion in a recognized pharmacopeia (ApexBio L1021).
• Compounds are provided as pre-dissolved 10 mM DMSO solutions, stable for 12 months at -20°C and up to 24 months at -80°C (ApexBio L1021).
• In OA models, 5-aminosalicylic acid (5-ASA) identified via HTS suppressed OSCAR-mediated repression of PPARγ and reduced COX-2-mediated inflammation in mice (Kim et al., 2024, DOI).
• 5-ASA improved cartilage thickness and ECM anabolic/catabolic balance when administered intra-articularly in DMM-induced OA mouse models (Kim et al., 2024, DOI).
• HTS workflows with the library enabled rapid screening of up to 3,287 compounds for novel protein-ligand interactions (Kim et al., 2024).

For further discussion on translational workflows and competitive positioning, see Translating Mechanisms into Medicines, which complements this article by mapping strategic routes for target identification, whereas the present piece details empirical evidence and compound stability parameters.

Applications, Limits & Misconceptions

Applications:

• High-throughput and high-content screening for oncology, neurodegenerative, and metabolic disease targets.
• Drug repositioning: repurposing clinically validated compounds for novel therapeutic indications.
• Mechanistic pathway analysis: dissecting receptor, enzyme, and signaling protein networks.
• Pharmacological target identification in disease-relevant models, including primary cells and organoids.

Common Pitfalls or Misconceptions

• The library is not a substitute for de novo chemical diversity libraries; it is restricted to FDA/EMA/HMA/CFDA/PMDA-approved or pharmacopeia-listed molecules.
• Compounds are provided in DMSO; aqueous solubility or compatibility with all assay types is not guaranteed.
• While clinically approved, compounds may have off-target or cytotoxic effects under non-clinical conditions.
• HTS results require orthogonal validation; library screening does not confirm clinical efficacy in new indications.
• The library does not include investigational new drugs (INDs) or unapproved experimental agents.

For workflow optimizations and troubleshooting strategies, see Maximizing High-Throughput Discovery. This article extends practical guidance by specifying compound stability, mechanisms, and recent data-driven repositioning examples.

Workflow Integration & Parameters

• Compounds are formatted for 96-well plates, deep well plates, or 2D barcoded screw-top tubes, supporting automation and sample tracking (ApexBio L1021).
• Shipping is performed on blue ice for evaluation samples; room temperature or blue ice shipping is available for other sizes.
• Solutions maintain stability for 12 months at -20°C and up to 24 months at -80°C, minimizing degradation risk.
• Each compound is annotated with mechanism, regulatory status, and molecular structure, facilitating in silico and empirical screens.
• HTS and HCS platforms can directly integrate with library formats for streamlined screening and automated data capture (Atomic Evidence).

For unique strategies in combination therapy development and pharmacological target identification, DiscoveryProbe™: Empowering Combination Therapy offers approaches extended here by demonstrating library-linked mechanistic discoveries in OA and signaling research.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) enables high-confidence, mechanism-driven screening for rapid drug repositioning and target validation. Its regulatory curation, stability, and annotation support translational research across disease models. Recent studies, such as the identification of 5-ASA as a disease-modifying OA agent, underscore the library’s capacity to accelerate novel therapeutic discovery (Kim et al., 2024). Ongoing integration with AI/ML and multi-omics platforms is expected to further increase the impact of this resource in biomedical innovation.